Boston, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, will attend VIVE 2024, Feb. 25-28, in Los Angeles. Executives will be onsite to discuss the company’s hybrid care enablement platform, virtual nursing, automated care, and digital behavioral health programs and how technology can address workforce shortages, access to care, the mental health crisis and other industry issues.
In addition, two Amwell executives will lead or participate in ViVE panels:
Schoenberg will lead a discussion with leaders from Providence, NewYork-Presbyterian, and Froedtert & Medical College of Wisconsin and Inception Health. The conversation will center on digital-first care delivery using tools such as remote monitoring devices and wearable technology to foster a more proactive and personalized approach to healthcare outside the hospital setting.
Horner will join colleagues from Amazon Pharmacy, knownwell, and Vida Health, for a discussion about whether the industry can create a sustainable model to cover the costs of GLP-1s, virtual primary care as a healthcare solution for weight-related co-morbidities and curbing the trajectory of obesity rates.
For more information about Amwell at ViVE or to talk with a company leader during the event, contact This email address is being protected from spambots. You need JavaScript enabled to view it..
About Amwell
Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.

| Last Trade: | US$4.50 |
| Daily Change: | -0.16 -3.43 |
| Daily Volume: | 140,632 |
| Market Cap: | US$66.240M |
November 04, 2025 August 05, 2025 May 01, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load